NL-OMON31056
Not yet recruiting
Not Applicable
Chronic rhinosinusitis and nasal polyposis a GA2LEN cohort study - Chronic rhinosinusitis and nasal polyposis a GA2LEN cohort study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- nasal polyps
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 125
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. The subject understands the study procedures and agrees to participate by signing the consent form.
- •2\. The subject is male or female, at least 18 years of age but no more than 60 years of age
- •3\. Subjects must be in good health, free of any clinically significant disease that would interfere with the study or procedures or compromise his/her safety.
- •4\.Diagnosis of chronic rhinosinusitis:
- •The diagnosis of chronic rhinosinusitis (with or without nasal polyps, including fungal disease, Cystic fibrosis, etc.) based on the EP3OS definition ;For controls: Controls are patients undergoing surgery such as septoplasty or septorhinoplasty, who have no medical history or symptoms of any form of chronic rhinosinusitis
Exclusion Criteria
- •1\. Patients with a recent acute exacerbation of rhinosinusitis (past two weeks) are not allowed to participate
- •2\. The subject had functional endoscopic sinus surgery (FESS) before, with removal of parts of the lateral nasal wall. Polypectomy, septal or inferior turbinate surgery is allowed.
- •3\. Women must not be pregnant or breast feeding
- •4\. The subject is a current or recent past abuser of alcohol or illicit drugs
- •5\. The subject has a history of malignancy, is known to be positive for HIV, has immunodeficiencies or other states that are considered to interfere with study conduct or scientific interpretations.
- •6\. Subjects must not be known to have sarcoidosis
- •7\. Subjects must not be known to have any type of vasculitis (including Wegener)
- •8\. Subjects must not be known to be positive to hepatitis B surface antigen or C antibodies.
- •9\. The subject cannot read or comprehend written material, or is in the opinion of the investigator, for other reasons unlikely to understand and follow the study procedures.
- •10\. The subject is mentally or legally incapacitated preventing informed consent from being obtained.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Prevention of recurrence of nasal polyposis after endoscopic sinus surgeryHealth Condition 1: J330- Polyp of nasal cavityCTRI/2019/06/019707Pondicherry Institute of Medical Sciences
Recruiting
Phase 1
Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumabChronic rhinosinusitis with nasal polyposisMedDRA version: 20.1Level: PTClassification code: 10080060Term: Chronic rhinosinusitis with nasal polyps Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Therapeutic area: Diseases [C] - Otorhinolaryngologic Diseases [C09]CTIS2022-502250-14-00Rigshospitalet220
Completed
Phase 3
Effect of Mepolizumab in Severe Bilateral Nasal PolypsNasal PolypsNCT03085797GlaxoSmithKline414
Completed
Phase 1
The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic RhinosinusitisRhinosinusitisNCT02403479Lawson Health Research Institute22
Completed
Not Applicable
Rhinosinusitis and nasal polyps in adults with Cystic FibrosisCystic Fibrosis: mucoviscidosisrhinosinusitis: paranasal sinus infectionsinusitis100386861001981510046304NL-OMON36309HagaZiekenhuis100